AP-2 is a family of developmentally regulated transcription factors which also play a role in breast cancer and melanoma. AP-2? may be important in cardiac and kidney development. The AP-2 transcription factors form the OB2 complex that has been shown to up-regulate c-erb-B2 transcription.
| Inventor | Institute |
|---|---|
| Helen Hurst | Queen Mary University of London |
| Cat. #: | 151254 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Genetics;Tissue-specific biology |
| Application: | ChIP ; IHC ; WB |
| Target: | Activating Protein 2 (AP-2) alpha (Human) |
| Reactivity: | Human |
| Clone: | AP2a 8G8/5 |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | AP-2 is a family of developmentally regulated transcription factors which also play a role in breast cancer and melanoma. AP-2?ĂÂ may be important in cardiac and kidney development. The AP-2 transcription factors form the OB2 complex that has been shown to up-regulate c-erb-B2 transcription. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Molecular weight: | 50 kDa |
| Immunogen: | Bacterialy expressed AP-2a/AP-2g fusion protein. |
| Myeloma used: | Sp2/0-Ag14 |
| Target background: | AP-2 is a family of developmentally regulated transcription factors which also play a role in breast cancer and melanoma. AP-2? may be important in cardiac and kidney development. The AP-2 transcription factors form the OB2 complex that has been shown to up-regulate c-erb-B2 transcription. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.82 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Nordentoft et al. 2011. BMC Cancer. 11:135. PMID: 21489314. Increased expression of transcription factor TFAP2a correlates with chemosensitivity in advanced bladder cancer. Bennett et al. 2009. PLoS One. 4(9):e6931. PMID: 19742317. AP-2alpha induces epigenetic silencing of tumor suppressive genes and microsatellite instability in head and neck squamous cell carcinoma. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151038 | Anti-Cytochrome P450 4A2, 4A3 [Clo4] |
Key Info
Anti-Cytochrome P450 4A2, 4A3 [Clo4]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.